BR112018067922A2 - compostos antibacterianos e seus usos - Google Patents
compostos antibacterianos e seus usosInfo
- Publication number
- BR112018067922A2 BR112018067922A2 BR112018067922A BR112018067922A BR112018067922A2 BR 112018067922 A2 BR112018067922 A2 BR 112018067922A2 BR 112018067922 A BR112018067922 A BR 112018067922A BR 112018067922 A BR112018067922 A BR 112018067922A BR 112018067922 A2 BR112018067922 A2 BR 112018067922A2
- Authority
- BR
- Brazil
- Prior art keywords
- antibacterial compounds
- compounds
- tuberculosis
- formula
- treatment
- Prior art date
Links
- 150000001875 compounds Chemical class 0.000 title abstract 2
- 230000000844 anti-bacterial effect Effects 0.000 title 1
- 150000003839 salts Chemical class 0.000 abstract 1
- 201000008827 tuberculosis Diseases 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
- A61P31/06—Antibacterial agents for tuberculosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/47—Quinolines; Isoquinolines
- A61K31/4709—Non-condensed quinolines and containing further heterocyclic rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D215/00—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems
- C07D215/02—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom
- C07D215/16—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D215/20—Oxygen atoms
- C07D215/22—Oxygen atoms attached in position 2 or 4
- C07D215/227—Oxygen atoms attached in position 2 or 4 only one oxygen atom which is attached in position 2
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/06—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
- C07D405/06—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
- C07D409/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
- C07D409/06—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
- C07D409/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Communicable Diseases (AREA)
- Oncology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Epidemiology (AREA)
- Pulmonology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
Abstract
a presente invenção está relacionada aos compostos de fórmula (i) incluindo qualquer forma estereoquimicamente isomérica deste, ou sais farmaceuticamente aceitáveis deste, para o tratamento de tuberculose.
Priority Applications (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| BR122023025283A BR122023025283A2 (pt) | 2016-03-07 | 2017-03-07 | Compostos antibacterianos e seus usos |
| BR122021024097-3A BR122021024097B1 (pt) | 2016-03-07 | 2017-03-07 | Composto antibacteriano, uso do mesmo e composição farmacêutica |
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201662304661P | 2016-03-07 | 2016-03-07 | |
| US62/304,661 | 2016-03-07 | ||
| PCT/US2017/021031 WO2017155909A1 (en) | 2016-03-07 | 2017-03-07 | Antibacterial compounds and uses thereof |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| BR112018067922A2 true BR112018067922A2 (pt) | 2019-01-15 |
| BR112018067922B1 BR112018067922B1 (pt) | 2024-02-06 |
Family
ID=59790723
Family Applications (3)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| BR112018067922-4A BR112018067922B1 (pt) | 2016-03-07 | 2017-03-07 | Compostos antibacterianos, usos dos mesmos e composições farmacêuticas |
| BR122023025283A BR122023025283A2 (pt) | 2016-03-07 | 2017-03-07 | Compostos antibacterianos e seus usos |
| BR122021024097-3A BR122021024097B1 (pt) | 2016-03-07 | 2017-03-07 | Composto antibacteriano, uso do mesmo e composição farmacêutica |
Family Applications After (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| BR122023025283A BR122023025283A2 (pt) | 2016-03-07 | 2017-03-07 | Compostos antibacterianos e seus usos |
| BR122021024097-3A BR122021024097B1 (pt) | 2016-03-07 | 2017-03-07 | Composto antibacteriano, uso do mesmo e composição farmacêutica |
Country Status (12)
| Country | Link |
|---|---|
| US (2) | US10508097B2 (pt) |
| EP (2) | EP4148053A1 (pt) |
| JP (3) | JP6997095B2 (pt) |
| KR (2) | KR102355154B1 (pt) |
| CN (1) | CN109069514B (pt) |
| AU (2) | AU2017229128B2 (pt) |
| BR (3) | BR112018067922B1 (pt) |
| CA (2) | CA3016068C (pt) |
| EA (1) | EA201891644A1 (pt) |
| ES (1) | ES2934785T3 (pt) |
| WO (1) | WO2017155909A1 (pt) |
| ZA (1) | ZA201805523B (pt) |
Families Citing this family (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| BR112018067922B1 (pt) * | 2016-03-07 | 2024-02-06 | The Global Alliance For Tb Drug Development, Inc | Compostos antibacterianos, usos dos mesmos e composições farmacêuticas |
| CN108929310A (zh) * | 2018-06-29 | 2018-12-04 | 湖南华腾制药有限公司 | 一种二芳基喹啉衍生物的制备方法 |
| CN108707138A (zh) * | 2018-06-29 | 2018-10-26 | 湖南华腾制药有限公司 | 一种二芳基喹啉衍生物的制备方法 |
| CN108689998A (zh) * | 2018-06-29 | 2018-10-23 | 湖南华腾制药有限公司 | 一种二芳基喹啉衍生物的制备方法 |
| CN108840857A (zh) * | 2018-07-10 | 2018-11-20 | 湖南华腾制药有限公司 | 一种喹啉衍生物的制备方法 |
| WO2020047596A1 (en) * | 2018-09-04 | 2020-03-12 | Monash University | Antibacterial compounds and methods of use |
| CN109535068B (zh) * | 2018-12-26 | 2022-07-29 | 中国药科大学 | 吡啶取代查尔酮类化合物或其可药用的盐及其制备方法和用途 |
| WO2021057190A1 (zh) * | 2019-09-29 | 2021-04-01 | 上海阳帆医药科技有限公司 | 喹啉类化合物、其制备方法和用途 |
Family Cites Families (20)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP1527050B1 (en) * | 2002-07-25 | 2010-04-07 | Janssen Pharmaceutica N.V. | Quinoline derivatives and their use as mycobacterial inhibitors |
| KR20130024969A (ko) | 2004-05-28 | 2013-03-08 | 얀센 파마슈티카 엔.브이. | 약물 내성 마이코박테리아 질환 치료를 위한 치환된 퀴놀린 유도체의 용도 |
| EE05394B1 (et) | 2004-12-24 | 2011-04-15 | Janssen Pharmaceutica N.V. | Kinoliinihendid kasutamiseks latentse tuberkuloosi ravis |
| BG66437B1 (bg) * | 2004-12-24 | 2014-07-31 | Janssen Pharmaceutica N.V. | Използване на хинолинови съединения за лечение на латентна туберкулоза |
| NZ563819A (en) * | 2005-05-25 | 2011-01-28 | Janssen Pharmaceutica Nv | Process for preparing (alpha S, beta R)-6-bromo-alpha-[2-(dimethylamino)ethyl]-2-methoxy-alpha-1-napthalenyl-beta-phenyl-3-quinolineethanol (R207910) |
| JP5349730B2 (ja) * | 2005-06-09 | 2013-11-20 | ジヤンセン・フアーマシユーチカ・ナームローゼ・フエンノートシヤツプ | 抗バクテリア剤としてのキノリン誘導体 |
| JO2837B1 (en) * | 2005-08-03 | 2014-09-15 | جانسن فارمسيتكا ان في | Quinoline derivatives acting as antibacterial agents |
| JO2684B1 (en) * | 2006-12-06 | 2013-03-03 | جانسين فارماسوتيكا ان في | Quinoline antibacterial derivatives |
| JO2970B1 (en) * | 2006-12-06 | 2016-03-15 | جانسين فارماسوتيكا ان. في | Quinoline antibacterial derivatives |
| JO3271B1 (ar) * | 2006-12-06 | 2018-09-16 | Janssen Pharmaceutica Nv | مشتقات الكوينولين المضادة للجراثيم |
| EP2195311B1 (en) | 2007-08-17 | 2011-03-23 | Actelion Pharmaceuticals Ltd. | Pyridine derivatives as s1p1/edg1 receptor modulators |
| WO2009083553A1 (en) | 2007-12-31 | 2009-07-09 | Rheoscience A/S | Azine compounds as glucokinase activators |
| WO2009091324A1 (en) * | 2008-01-14 | 2009-07-23 | Jyoti Chattopadhyaya | Quinoline, naphthalene and conformationally constrained quinoline or naphthalene derivates as anti-mycobacterial agents |
| NZ591115A (en) | 2008-09-26 | 2012-10-26 | Boehringer Ingelheim Int | Azaindazole compounds as ccr1 receptor antagonists |
| EP2375899B1 (en) | 2009-01-12 | 2015-02-25 | Array Biopharma Inc. | Piperidine-containing compounds and use thereof in the treatment of diabetes |
| WO2010100475A1 (en) | 2009-03-02 | 2010-09-10 | Astrazeneca Ab | Hydroxamic acid derivatives as gram-negative antibacterial agents |
| AU2013254674B2 (en) * | 2012-04-27 | 2017-02-02 | Janssen Pharmaceutica Nv | Antibacterial quinoline derivatives |
| WO2014014845A1 (en) * | 2012-07-18 | 2014-01-23 | Vertex Pharmaceuticals Incorporated | Combination therapy comprising|1 -ethyl-3-[5-[2-{1 -hydroxy-1 -methyl-ethyl}pyrimidin-5-yl]-7-(tetra hydrofuran-2-|yl}-1 h-benzimidazol-2-yl]urea and derivatives thereof to treat mycobacterium|diseases |
| EP3170810B1 (en) * | 2014-07-14 | 2018-09-19 | Cisen Pharmaceutical Co., Ltd. | Pyridine derivatives and anti-mycobacterial use thereof |
| BR112018067922B1 (pt) * | 2016-03-07 | 2024-02-06 | The Global Alliance For Tb Drug Development, Inc | Compostos antibacterianos, usos dos mesmos e composições farmacêuticas |
-
2017
- 2017-03-07 BR BR112018067922-4A patent/BR112018067922B1/pt active IP Right Grant
- 2017-03-07 US US16/079,812 patent/US10508097B2/en active Active
- 2017-03-07 KR KR1020187028857A patent/KR102355154B1/ko active IP Right Grant
- 2017-03-07 ES ES17763848T patent/ES2934785T3/es active Active
- 2017-03-07 CN CN201780028310.6A patent/CN109069514B/zh active Active
- 2017-03-07 BR BR122023025283A patent/BR122023025283A2/pt unknown
- 2017-03-07 AU AU2017229128A patent/AU2017229128B2/en active Active
- 2017-03-07 WO PCT/US2017/021031 patent/WO2017155909A1/en active Application Filing
- 2017-03-07 CA CA3016068A patent/CA3016068C/en active Active
- 2017-03-07 EP EP22202329.3A patent/EP4148053A1/en active Pending
- 2017-03-07 KR KR1020227002071A patent/KR102480410B1/ko active IP Right Grant
- 2017-03-07 EA EA201891644A patent/EA201891644A1/ru unknown
- 2017-03-07 EP EP17763848.3A patent/EP3426255B1/en active Active
- 2017-03-07 JP JP2018546705A patent/JP6997095B2/ja active Active
- 2017-03-07 BR BR122021024097-3A patent/BR122021024097B1/pt active IP Right Grant
- 2017-03-07 CA CA3226824A patent/CA3226824A1/en active Pending
-
2018
- 2018-08-17 ZA ZA201805523A patent/ZA201805523B/en unknown
-
2019
- 2019-10-14 US US16/600,651 patent/US10981891B2/en active Active
-
2021
- 2021-08-27 JP JP2021138560A patent/JP7453946B2/ja active Active
-
2022
- 2022-06-10 AU AU2022204071A patent/AU2022204071B2/en active Active
-
2023
- 2023-12-04 JP JP2023204901A patent/JP2024028841A/ja active Pending
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| BR112018067922A2 (pt) | compostos antibacterianos e seus usos | |
| BR112018000635A2 (pt) | compostos aza substituídos como inibidores irak-4 | |
| BR112016029853A2 (pt) | compostos de indazol substituído como inibidores de irak4 | |
| BR112018000624A2 (pt) | compostos de indazol e azaindazol como inibidores de irak-4 | |
| BR112017013491A2 (pt) | compostos de pirimidina fundida para o tratamento de hiv | |
| CO2018000113A2 (es) | Compuestos derivados de 2-(4-fenil-2-oxopiridin-1-(2h)-il)alcanoilamina | |
| DOP2016000173A (es) | Heteroarilos y usos de estos | |
| TW201613872A (en) | IRAK4 inhibiting agents | |
| EA201791420A1 (ru) | Соединения триазолопиримидина и их применения | |
| BR112017013440A2 (pt) | compostos de isoquinolina para o tratamento de hiv | |
| BR112017013936A2 (pt) | inibidores de bace1 seletivos. | |
| ECSP17035750A (es) | Composición de liberación modificada de orlistat y acarbosa para el tratamiento de la obesidad y trastornos metabólicos relacionados | |
| PH12016501988A1 (en) | Antibacterial compounds | |
| EA201890186A1 (ru) | Применение штаммов микробактерий для получения антибактериальных агентов | |
| EA201790687A1 (ru) | Хинолинкарбоксамиды для применения в лечении множественной миеломы | |
| EA201790464A1 (ru) | Гетеробициклические соединения и их применение для лечения туберкулеза | |
| BR112018011670A2 (pt) | compostos antibacterianos | |
| DOP2018000049A (es) | Compuestos para uso en aplicaciones antibacterianas | |
| BR112015016033A8 (pt) | composições farmacêuticas para tratamento de infecções por bactérias, e seus usos | |
| BR112015018442A2 (pt) | compostos de derivados de ciclohexeno biaril- ou heterocíclico biaril-substituído como inibidores de cetp | |
| BR112017016819A2 (pt) | compostos de diaza-benzofluorantreno | |
| CL2015003431A1 (es) | Derivados de piridona para el tratamiento de infecciones virales y enfermedades adicionales | |
| BR112016024467A2 (pt) | compostos e métodos para a prevenção ou o tratamento da malária | |
| BR112019027387A8 (pt) | Composições imunogênicas | |
| DOP2016000325A (es) | Compuestos, composición farmacéutica y su uso en el tratamiento de enfermedades neurodegenerativas |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| B06F | Objections, documents and/or translations needed after an examination request according [chapter 6.6 patent gazette] | ||
| B07D | Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette] |
Free format text: DE ACORDO COM O ARTIGO 229-C DA LEI N? 10196/2001, QUE MODIFICOU A LEI N? 9279/96, A CONCESS?O DA PATENTE EST? CONDICIONADA ? ANU?NCIA PR?VIA DA ANVISA. CONSIDERANDO A APROVA??O DOS TERMOS DO PARECER N? 337/PGF/EA/2010, BEM COMO A PORTARIA INTERMINISTERIAL N? 1065 DE 24/05/2012, ENCAMINHA-SE O PRESENTE PEDIDO PARA AS PROVID?NCIAS CAB?VEIS. |
|
| B06F | Objections, documents and/or translations needed after an examination request according [chapter 6.6 patent gazette] | ||
| B06I | Publication of requirement cancelled [chapter 6.9 patent gazette] |
Free format text: ANULADA A PUBLICACAO CODIGO 6.6.1 NA RPI NO 2631 DE 08/06/2021 POR TER SIDO INDEVIDA. |
|
| B07E | Notification of approval relating to section 229 industrial property law [chapter 7.5 patent gazette] | ||
| B350 | Update of information on the portal [chapter 15.35 patent gazette] | ||
| B06W | Patent application suspended after preliminary examination (for patents with searches from other patent authorities) chapter 6.23 patent gazette] | ||
| B06A | Patent application procedure suspended [chapter 6.1 patent gazette] | ||
| B09A | Decision: intention to grant [chapter 9.1 patent gazette] | ||
| B154 | Notification of filing of divisional application [chapter 15.50 patent gazette] |
Free format text: O PEDIDO FOI DIVIDIDO NO BR122023025283-7 PROTOCOLO 870230106010 EM 01/12/2023 14:20. |
|
| B16A | Patent or certificate of addition of invention granted [chapter 16.1 patent gazette] |
Free format text: PRAZO DE VALIDADE: 20 (VINTE) ANOS CONTADOS A PARTIR DE 07/03/2017, OBSERVADAS AS CONDICOES LEGAIS |